Harvard Bioscience, Inc.
NNASDAQ:HBIOCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- John D. Duke
- Full Time Employees
- 339
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 84 October Hill Road Holliston MA United States 01746
- IPO Date
- Dec 7, 2000
- CIK
- 0001123494
- Website
- harvardbioscience.com
- Similar Companies
- Business
- Harvard Bioscience, Inc. (Nasdaq: HBIO) develops, manufactures, and markets a broad range of technologies, products, and services that enable fundamental research, discovery, and preclinical testing in life sciences applications worldwide; its core offerings span cellular and molecular technologies, including syringe and peristaltic infusion pumps, electroporation and electrofusion instruments under the BTX brand, amino acid analyzers and UV/visible spectrophotometers from Biochrom, microvolume spectrophotometers from BioDrop, precision instrumentation such as data acquisition systems and microelectrode arrays from HEKA, Multi Channel Systems (MCS), and Warner Instruments, as well as CMA microdialysis solutions; and preclinical safety and efficacy products comprising implantable telemetry systems for cardiovascular, respiratory, and metabolic data collection from Data Sciences International (DSI), behavioral research systems, isolated organ and surgical products, plethysmograph chambers, inhalation exposure systems, and GLP-capable data acquisition from Panlab, Hugo Sachs Elektronik, and Buxco brands. Founded in 1901 with roots in Harvard Apparatus and headquartered in Holliston, Massachusetts, the company operates through 12 subsidiaries with manufacturing facilities in the United States, Germany, and Spain, serving academic institutions, pharmaceutical firms, biotechnology companies, and contract research organizations primarily in the United States, Europe, and internationally. In recent developments, Harvard Bioscience expanded its distribution agreement with Fisher Scientific in September 2025 to enhance U.S. and European market penetration for key products including pumps, spectrophotometers, and BTX electroporation systems, while reporting Q3 2025 revenues of $20.6 million, a gross margin of 58.4%, positive operating cash flow, and plans to refinance or repay debt in Q4 2025 amid ongoing cost reductions and innovations like MeshMEA organoid systems and SoHo telemetry.
Company News
Harvard Bioscience to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum
Harvard Bioscience Schedules Third Quarter 2026 Earnings Conference Call for November 10, 2026 at 8:00 AM ET
Harvard Bioscience Announces Creation of Scientific Advisory Board
Harvard Bioscience, Inc. (HBIO) Q2 2026 Earnings Call Transcript
Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET
Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET
Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript
Harvard Bioscience Announces First Quarter 2026 Financial Results
Harvard Bioscience to Participate in Upcoming Investor Conferences
Harvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8:00 AM ET
Harvard Bioscience Q4 Earnings Call Highlights
Harvard Bioscience, Inc. (HBIO) Q4 2025 Earnings Call Transcript
Harvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financial Results
Harvard Bioscience Announces Reverse Stock Split
Harvard Bioscience (NASDAQ:HBIO) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened
Harvard Bioscience to Participate in KeyBanc's Virtual Healthcare Forum
Harvard Bioscience Schedules Fourth Quarter 2025 Earnings Conference Call for March 12, 2026 at 8:00 AM ET
Harvard Bioscience (NASDAQ:HBIO) Stock Crosses Below 200 Day Moving Average – Time to Sell?
Harvard Bioscience Announces Preliminary Fourth Quarter Financial Results, Positive Outlook for 2026 & Outlines Long-Term Strategic Focus Areas
Harvard Bioscience Announces Strategic Consolidation of Manufacturing Operations to Improve Efficiency and Support Long-Term Growth